

# Comparative Effectiveness of Coronary CT Angiography and Standard of Care for Evaluating Acute Chest Pain: A Living Systematic Review and Meta-Analysis

Maurício F. Barbosa, MD, PhD • Arzu Canan, MD • Yin Xi, PhD • Harold Litt, MD, PhD • Deborah B. Diercks, MD, MSc • Subny Abbara, MD • Fernando U. Kay, MD, PhD

From the Department of Radiology, Cardiothoracic Division (M.F.B., A.C., S.A., F.U.K.), Department of Radiology (Y.X.), and Department of Emergency Medicine (D.B.D.), UT Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390; and Department of Radiology, University of Pennsylvania, Philadelphia, Pa (H.L.). Received January 21, 2023; revision requested February 17; revision received June 26; accepted July 3. Address correspondence to F.U.K. (email: fernando.kay@utsouthwestern.edu).

Authors declared no funding for this work.

Conflicts of interest are listed at the end of this article.

Radiology: Cardiothoracic Imaging 2023; 5(4):e230022 • <https://doi.org/10.1148/ryct.230022> • Content codes: **CA** **CT**

**Purpose:** To perform a living systematic review and meta-analysis of randomized controlled trials comparing the effectiveness of coronary CT angiography (CCTA) and standard of care (SOC) in the evaluation of acute chest pain (ACP).

**Materials and Methods:** Multiple electronic databases were systematically searched, with the most recent search conducted on October 31, 2022. Studies were stratified into two groups according to the pretest probability for acute coronary syndrome (group 1 with predominantly low-to-intermediate risk vs group 2 with high risk). A meta-regression analysis was also conducted using participant risk, type of SOC used, and the use or nonuse of high-sensitivity troponins as independent variables.

**Results:** The final analysis included 22 randomized controlled trials (9379 total participants; 4956 assigned to CCTA arms and 4423 to SOC arms). There was a 14% reduction in the length of stay and a 17% reduction in immediate costs for the CCTA arm compared with the SOC arm. In group 1, the length of stay was 17% shorter and costs were 21% lower using CCTA. There was no evidence of differences in referrals to invasive coronary angiography, myocardial infarction, mortality, rate of hospitalization, further stress testing, or readmissions between CCTA and SOC arms. There were more revascularizations (relative risk, 1.45) and medication changes (relative risk, 1.33) in participants with low-to-intermediate acute coronary syndrome risk and increased radiation exposure in high-risk participants (mean difference, 7.24 mSv) in the CCTA arm compared with the SOC arm. The meta-regression analysis found significant differences between CCTA and SOC arms for rate of hospitalization, further stress testing, and medication changes depending on the type of SOC ( $P < .05$ ).

**Conclusion:** The results support the use of CCTA as a safe, rapid, and less expensive in the short term strategy to exclude acute coronary syndrome in low- to intermediate-risk patients presenting with acute chest pain.

Supplemental material is available for this article.

Published under a CC BY 4.0 license.

Acute chest pain (ACP) is the second most common reason for adult patients to visit the emergency department (ED) in the United States, accounting for approximately 6.3% of all ED consultations (1). While a small portion of these patients will have acute coronary syndrome (ACS) as the underlying cause of their ACP, the serious consequences of missed diagnoses and nonspecific clinical manifestation pose a challenge to ED services for triaging such patients (2,3). Therefore, providers usually follow a cautious approach to ACP, frequently including a combination of close clinical observation, electrocardiography, serial cardiac biomarkers, and stress testing, which has contributed to the increasing use of health care resources (2). More recently, the American College of Cardiology and the American Heart Association jointly published the guideline for the evaluation and diagnosis of ACP to address heterogeneity of practice among health care institutions (4). This guideline incorporates best

practices based on accumulated evidence, including the role of emerging diagnostic tests such as coronary CT angiography (CCTA).

CCTA is a noninvasive imaging method with high accuracy for diagnosing obstructive coronary artery disease (CAD). CCTA's utility is driven by its high sensitivity and negative predictive value (5). Previous meta-analyses corroborate the safety of CCTA compared with the standard of care (SOC) in the evaluation of ACP (6–9) suggesting the potential for reductions in use of health care resources as measured by length of ED and hospital stays (LOS) and overall costs. However, recent randomized controlled trials (RCTs) failed to reproduce those results (10–12). Reconciliation of these conflicting data is imperative to consolidate the strategic role of CCTA for assessing ACP (4).

Living systematic reviews (LSRs) are tools for incorporating novel evidence longitudinally, even after the initial publication of a manuscript and especially

## Abbreviations

ACP = acute chest pain, ACS = acute coronary syndrome, CAD = coronary artery disease, CCTA = coronary CT angiography, ED = emergency department, ICA = invasive coronary angiography, LOS = length of stay, LSR = living systematic review, MI = myocardial infarction, RCT = randomized controlled trial, RR = risk ratio, SOC = standard of care

## Summary

The use of coronary CT angiography to evaluate individuals with low-to-intermediate risk for acute chest pain was associated with shorter length of emergency department and hospital stay and reduced immediate costs.

## Key Points

- Coronary CT angiography (CCTA) demonstrated effectiveness as a safety strategy for evaluation of participants presenting with acute chest pain, showing similar incidence of myocardial infarction (relative risk, 0.86; 95% CI: 0.66, 1.12), all-cause mortality (relative risk, 0.96; 95% CI: 0.59, 1.58), and cardiovascular mortality (relative risk, 1.35; 95% CI: 0.59, 3.09), compared with usual care, irrespective of pretest probability.
- The number of referrals for invasive coronary angiography after CCTA was not statistically different from standard of care irrespective of pretest probability. However, there were more revascularizations (relative risk, 1.45; 95% CI: 1.09, 1.93) and changes in medication (relative risk, 1.33; 95% CI: 1.06, 1.67) in participants with low-to-intermediate risk of acute coronary syndrome and increased radiation exposure (mean difference, 7.24 mSv; 95% CI: 4.55, 9.94) in higher-risk participants in the CCTA arm.
- The use of CCTA in low- to intermediate-risk participants was associated with a 17% reduction in length of stay and a 21% decrease in immediate costs.

## Keywords

Acute Coronary Syndrome, Chest Pain, Emergency Department, Coronary Computed Tomography, Usual Care

in fields where there is rapidly emerging evidence and when pending uncertainties exist (13). Our goal is to perform an LSR to evaluate the comparative effectiveness of CCTA versus SOC in the evaluation of ACP. We specifically focus on differences in resource utilization, clinical events, and survival. This LSR will continually update the data as new studies are published.

## Materials and Methods

### Literature Search and Study Selection

The Nested Knowledge living review platform ([www.nested-knowledge.com](http://www.nested-knowledge.com)) was used to perform this LSR and meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (14). The electronic databases PubMed, Cochrane Library, Web of Science, Embase, Scopus, Google Scholar, and ScienceDirect were systematically searched for RCTs comparing CCTA and SOC. SOC procedures included but were not limited to history taking, physical examination, electrocardiography, biomarkers, and stress testing in the evaluation of adult participants with ACP. The last search for inclusion of new studies was conducted on October 31, 2022. The

querying terms and respective search logic can be found in Appendix S1. Additionally, we searched the references of all included studies to identify potentially missed articles by the database searches.


After conducting the literature search, two independent readers (M.F.B. and A.C., cardiothoracic radiologists with 15 and 9 years of experience, respectively) screened the studies for inclusion, reviewing the title, abstract, and when necessary, the full text of the manuscript. Randomized trials published in peer-reviewed journals evaluating the effects of CCTA versus SOC on clinical outcomes and resource utilization in adult participants with ACP were included. Observational studies, abstracts, editorials, case series, and case reports were excluded. No language restriction was enforced. All disagreements were adjudicated by a third independent reader (F.U.K., cardiothoracic radiologist with 10 years of experience). To ensure the living component of our LSR, we plan to review the literature at least twice a year, so we will actively seek and incorporate new evidence as it becomes available.

### Data Extraction and Effect Measures

All data were collected from the published manuscripts and supplemental materials available online and inputted in the extraction module of Nested Knowledge. One author (M.F.B., cardiothoracic radiologist with 15 years of experience) abstracted data related to participant characteristics, including age, sex, race and ethnicity, body mass index, and cardiovascular risk factors (hypertension, hyperlipidemia, diabetes, smoking history, and family history of CAD), as well as outcomes, including LOS, number of invasive coronary angiographic (ICA) examinations performed, rate of revascularization, myocardial infarction (MI), all-cause mortality, cardiovascular mortality, time to diagnosis, further stress testing, repeat visits or hospitalizations, rate of hospitalization, heart failure, cardioembolic stroke, changes in medication, radiation exposure, participant satisfaction, and costs. Revascularization was defined as the sum of percutaneous coronary intervention and coronary artery bypass graft. Costs were converted to U.S. dollars using the market quotation on the extraction day. In instances of overlapping outcome data from the same population, we prioritized the longer follow-up period when analyzing hard clinical events such as MI and mortality. For all other data, we extracted information from the first published article. A second author (A.C., cardiothoracic radiologist with 9 years of experience) reviewed and validated all extracted data. Detailed results of this study search, screening, and data extraction process are hosted on the Nested Knowledge website (<https://nested-knowledge.com/nest/912>) (Fig S1).

### Study Risk of Bias and Certainty Assessment

Two authors (M.F.B. and F.U.K., cardiothoracic radiologists with 15 and 10 years of experience, respectively) scored the risk of bias for each study using the Cochrane Risk of Bias 2 (RoB 2) tool (15) and the certainty of the evidence us-



**Figure 1:** Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) flowchart demonstrates the screening process for identification of studies included. CCTA = coronary CT angiography, SOC = standard of care.

ing the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system (16). Disagreements were resolved by consensus.

### Data Synthesis and Publication Bias

Pooled relative risks and corresponding 95% CIs were calculated for binary clinical outcomes using random-effects models. Difference in means or ratio of means and 95% CIs were calculated for numerical continuous outcomes (LOS and costs were calculated with ratio of means and the radiation dose was calculated with difference in means), also using random-effects models. To understand the effects of different pretest probability on the pooled effects, we stratified the studies into two groups. Group 1 contains RCTs including

study samples with predominantly low-to-intermediate risk for ACS, while group 2 is composed of RCTs including participants with a higher risk for ACS. We chose a 10% prevalence of high-risk participants in the study sample according to the definition of ACS risk chosen by each study as the classification criterion to differentiate between groups 1 and 2. Our decision to use this particular cutoff point was based on the discrepant outcomes observed in the Cardiac CT in the Treatment of Acute Chest pain (CATCH) trial (17) in comparison to the American College of Radiology Imaging Network-Pennsylvania (ACRIN-PA) (18) and Multicenter Study to Rule Out Myocardial Infarction by Cardiac Computed Tomography (ROMICAT-II) (19) trials. The prevalence of high-risk participants in the CATCH trial was

approximately 10% which was higher than the other trials due to variations in eligibility criteria resulting in a greater prevalence of CAD among participants. Additionally, we designated any RCT that exclusively included participants with non-ST-segment elevation MI or elevated high-sensitive troponins as a high-risk cohort. Heterogeneity was assessed using Higgins and Thompson  $I^2$  statistic.  $I^2$  is the proportion of total variation observed between the trials attributable to differences between trials rather than sampling error (chance), with  $I^2$  values of less than 25%, between 25% and 75%, and greater than 75% corresponding to low, moderate, and high levels of heterogeneity, respectively. To assess the presence of publication bias, we employed a combination of visual inspection of funnel plots and conducted Egger tests for funnel plot asymmetry. This analysis was conducted for outcomes where a minimum of 10 studies were available. Finally, we conducted a meta-regression analysis, stratifying studies by patient risk category (group 1 vs group 2), type of SOC employed (ie, further testing at physician's discretion vs routine stress echocardiography or nuclear medicine stress perfusion), and the routine use versus no use of high-sensitivity troponins as independent variables. All analyses were done with R software (version 4.2.1; The R Foundation) with package meta version 5.5-0 (20). A  $P$  value less than .05 indicated a statistically significant difference.

## Results

### Study Selection and Characteristics

The results of the literature search are presented in Figure 1. After the exclusion of duplicated study entries, a total of 616 studies remained for screening. During the screening process, 565 studies were excluded based on title and abstract review, resulting in 51 articles for full-text review. Then, 29 studies were excluded because of lack of intervention or control arm; duplicated reports of the same research; incorrect study design (eg, not randomized); lack of relevant outcome; publication reporting only the study design; or because it was a review, editorial, commentary, or abstract. Finally, 22 RCTs (10–12,17–19,21–36) were included in the final analysis, representing a total of 9379 participants, with 4956 participants assigned to the CCTA arms and 4423 participants assigned to the SOC arms. The follow-up length ranged from 28 days to more than 5 years among studies. The main characteristics of the studies are summarized in Tables 1 and 2.

We found no evidence of a difference in the baseline patient demographic characteristics between CCTA and SOC arms, as listed in Table 3, although the prevalence of hyperlipidemia was slightly higher in the SOC arm in two studies (31,34). The mean age of all participants included was 55 years, with 5066 (54%) male participants and 4313 (46%) female participants. Table 4 serves as a summary of the key findings for the main outcomes.

### Length of Stay

The pooled data showed a reduction of 14% (95% CI: 5%, 22%) in LOS for the CCTA arm compared with SOC arm

(Fig 2). In group 1, considering the pooled data of 10 RCTs with 5551 participants, the LOS was 17% (95% CI: 8%, 26%) shorter following CCTA. However, in group 2, there was no evidence of a difference in the LOS between the two arms (ratio of means, 0.97; 95% CI: 0.81, 1.15).

### Referral for ICA

There was no evidence of a difference in the number of referrals for ICA between CCTA and SOC approaches (Fig 3). In group 1, considering 13 RCTs with 6650 participants, the risk ratio (RR) of ICA for CCTA versus SOC was 1.20 (95% CI: 0.98, 1.48). In group 2, considering four RCTs with 2729 participants, the RR of ICA for CCTA versus SOC was 0.87 (95% CI: 0.67, 1.14).

### Revascularization

There were more revascularizations after CCTA compared with the SOC (Fig 4). The overall absolute increase of revascularizations after CCTA was 38 per 1000 participants (95% CI: 8, 77). In group 1, including 12 RCTs with 6590 participants, the RR of revascularization for CCTA versus the SOC was 1.45 (95% CI: 1.09, 1.93). In group 2, including three RCTs with 2590 participants, the RR of revascularization for CCTA versus the SOC was 1.25 (95% CI: 0.74, 2.11).

### Myocardial Infarction

There was no evidence of a difference in the number of MIs between CCTA and SOC arms (Fig 5). In group 1, including nine RCTs with 5340 participants, the RR of MI for CCTA versus the SOC was 0.90 (95% CI: 0.58, 1.38). In group 2, including three RCTs with 2590 participants, the RR of MI for CCTA versus the SOC was 0.82 (95% CI: 0.56, 1.21).

### All-Cause Mortality

There was no evidence of a difference in all-cause mortality when comparing CCTA and SOC arms (Fig 6). In group 1, pooling 12 RCTs with 6588 participants, the RR of all-cause mortality for CCTA versus SOC was 0.83 (95% CI: 0.37, 1.88). In group 2, considering four RCTs with 2729 participants, the RR of all-cause mortality for CCTA versus SOC was 1.06 (95% CI: 0.56, 2.00).

### Cardiovascular Mortality

There was no evidence of a difference in cardiovascular mortality between CCTA and SOC arms (Fig 7). In group 1, nine RCTs with 5735 participants yielded a pooled RR for cardiovascular mortality of 1.53 (95% CI: 0.06, 37.40), while in group 2, four RCTs with 2729 participants yielded an RR of 1.34 (95% CI: 0.57, 3.16) between CCTA and SOC arms, respectively.

### Radiation Exposure

Overall, there was no evidence of a difference in radiation exposure between CCTA and SOC arms. However, consid-

**Table 1: Main Characteristics of the Included Studies**

Study	ACS Risk	No. of Participants	Intervention Details	Follow-up	Primary End Point Results	Main Secondary End Point Results	Other Important Findings
Goldstein et al JACC 2007 (21)	Low	197	Patients enrolled at the ED; CCTA available 7 am–6 pm; SOC: SPECT-MPI; CCTA: >70% stenosis referred to ICA	6 months	No test complications or MACE in both arms	Efficacy in ACS detection similar between arms	Shorter time to diagnosis and lower costs in CCTA arm <sup>†</sup>
Chang et al Am Heart J 2008 (22)	Low to high	266	Patients enrolled at the ED; CCTA readily available; SOC: ECG and BM; further stress testing at attending physician discretion	30 days	No difference in the number of diagnoses but fewer unnecessary admissions in CCTA arm	No difference in ED LOS <sup>‡</sup>	No MACE in the follow-up for CCTA arm
Miller et al Acad Emerg Med 2011 (23)	Low to intermediate	60	Patients enrolled at the ED; CCTA available from Monday to Friday 7 am–4 pm; SOC: ECG and BM	90 days	No significant difference in costs <sup>‡</sup>	More CAD diagnosis in CCTA arm	Fewer hospital admission and readmission in CCTA arm
CT-STAT, Goldstein et al JACC 2011 (24)	Low	699	Patients enrolled at the ED; CCTA readily available; SOC: SPECT-MPI	6 months	Reduced time to diagnosis in CCTA arm <sup>†</sup>	Lower costs for CCTA arm <sup>†</sup>	No difference in MACE
ACRIN-PA, Litt et al NEJM 2012 (18)	Low to intermediate	1370	Patients enrolled at the ED and after admission (three sites); CCTA readily available; SOC: stress testing at attending physician's discretion	30 days	No death or MI in CCTA arm	Higher rate of discharge in CCTA arm <sup>†</sup>	Shorter LOS in CCTA arm <sup>†</sup>
ROMICAT-II, Hoffmann et al NEJM 2012 (19)	Intermediate	1000	Patients enrolled at the ED; CCTA available during weekday hours; SOC: further stress testing at attending physician's discretion	28 days	Reduced LOS in CCTA arm <sup>†</sup>	Reduced time to diagnosis and higher rate of discharge in CCTA arm <sup>†</sup>	Similar costs but more downstream testing and higher radiation exposure in CCTA arm
CATCH, Linde et al Int J Cardiol 2013 (17)	Low to high	576	Patients enrolled after hospitalization; inclusion criteria: patients who could be discharged within 24 hours and clinical indication for further testing; SOC: exercise bicycle and/or SPECT-MPI	4 months	Increased PPV for CCTA arm	Increased ICA referral and revascularization in CCTA arm <sup>§</sup>	More clinical events in SOC arm during follow-up

**(Table 1 continues)**

**Table 1 (continued): Main Characteristics of the Included Studies**

Study	ACS Risk	No. of Participants	Intervention Details	Follow-up	Primary End Point Results	Main Secondary End Point Results	Other Important Findings
CT-COMPARE, Hamilton-Craig et al Int J Cardiol 2014 (25)	Low to intermediate	562	Patients enrolled at the ED; CCTA available 8 am–10 pm, including weekends; SOC: treadmill exercise ECG	1 year	Improved diagnostic accuracy with CCTA arm <sup>†</sup>	LOS reduced in CCTA arm <sup>†</sup>	Increased downstream testing but lower costs for CCTA arm <sup>†</sup>
CATCH, Linde et al JACC 2015 (26)	Low to high	576	Patients enrolled after hospitalization; inclusion criteria: patients who could be discharged within 24 hours and clinical indication for further testing; SOC: exercise bicycle and SPECT-MPI	>1 year	Better long-term composite outcomes with CCTA arm	Reduced MACE in CCTA arm	NA
PROSPECT, Levsky et al Ann Int Med 2015 (27)	Intermediate	400	Patients enrolled in telemetry-monitored wards; CCTA results readily available but scanners were not; SOC: SPECT-MPI	>1 year	No difference in number of catheterizations not leading to revascularization	No difference in LOS <sup>‡</sup>	Reduced radiation exposure and better patient experience in CCTA arm
BEACON, Dedic et al* JACC 2016 (28)	Low to high	500	Patients enrolled at the ED; CCTA readily available; SOC: further stress testing at attending physician's discretion	30 days	No difference in number of patients requiring revascularization	No significant difference in discharge or LOS <sup>‡</sup>	Lower costs and less outpatient testing in CCTA arm <sup>†</sup>
Nabi et al J Nucl Med 2016 (29)	Low to high	598	Patients enrolled after hospitalization; CCTA available during weekdays, 7 am–5 pm; SOC: SPECT-MPI	>6 months	Reduced LOS in CCTA arm <sup>†</sup>	Reduced time to diagnosis in CCTA arm <sup>†</sup>	Similar overall costs and higher radiation exposure in CCTA arm <sup>‡</sup>
ACRIN-PA, Hollander et al Ann Emerg Med 2016 (30)	Low to intermediate	1370	Patients enrolled at the ED and after admission (three sites); CCTA readily available; SOC: stress testing at attending physician's discretion	1 year	No difference in MACE	No difference in ED revisits or hospital admissions	No difference in subsequent cardiac testing

(Table 1 continues)

**Table 1 (continued): Main Characteristics of the Included Studies**

Study	ACS Risk	No. of Participants	Intervention Details	Follow-up	Primary End Point Results	Main Secondary End Point Results	Other Important Findings
PERFECT, Uretsky et al J Nucl Cardiol 2017 (31)	Low	411	Patients enrolled after hospitalization; CCTA available on weekdays, 8 am–5 pm; SOC: stress echocardiography or SPECT-MPI	1 year	No difference in time to discharge or new medication <sup>†</sup>	No difference in downstream testing or hospitalization	Higher number of ICA and PCI in CCTA arm <sup>§</sup>
ACRIN-PA, Chang et al Circul 2017 (32)	Low to intermediate	1370	Patients enrolled at the ED and 1 year after admission (three sites); CCTA readily available; SOC: stress testing at attending physician's discretion	1 year	No difference in statins but lower rate of aspirin initiation in CCTA arm	Patients with significant stenosis at CCTA more likely to start new medication	Patients without stenosis at CCTA less likely to start new medication
Levsky et al JACC 2018 (33)	Low to intermediate	400	Patients enrolled at the ED; CCTA available during daytime on weekdays; SOC: stress echocardiography	2 years	Higher hospitalization rate in CCTA arm	Longer LOS for CCTA arm <sup>§</sup>	Increased MACE and radiation exposure in CCTA arm
CARMENTA, Smulders et al* JACC 2019 (34)	NSTEMI	139	Patients enrolled at the ED; three-arm study including cardiac MRI; CCTA readily available; SOC: further stress testing at attending physician's discretion	1 year	CCTA reduce referral to ICA <sup>†</sup>	Similar outcome	Increased radiation exposure in CCTA arm
PROSPECT, Goldman et al J Nucl Cardiol 2020 (35)	Intermediate	400	Patients enrolled in telemetry-monitored wards; CCTA readily available; SOC: SPECT-MPI	>1 year	More incidental findings in CCTA arm	NA	NA
Piñeiro-Portela et al Rev Esp Cardiol 2021 (36)	Low to intermediate	203	Patients enrolled after hospitalization, weekdays 8 am–3 pm CCTA available 1 day per week; SOC: stress echocardiography	5 years	No difference in the combination of hard events, revascularization, and readmission	No difference in costs <sup>‡</sup>	No difference in hard events (death and nonfatal MI)

**(Table 1 continues)**

**Table 1 (continued): Main Characteristics of the Included Studies**

Study	ACS Risk	No. of Participants	Intervention Details	Follow-up	Primary End Point Results	Main Secondary End Point Results	Other Important Findings
RAPID-CTCA, Gray et al* BMJ 2021 (10)	Low to high	1748	Patients enrolled at the ED, acute medical services, and cardiology departments; CCTA results readily available; SOC: stress testing at attending physician's discretion	1 year	No difference in death or nonfatal myocardial infarction	Fewer ICA with CCTA arm†	Greater patient satisfaction in CCTA arm
RAPID-CTCA, Gray et al* Health Technol Assess 2022 (12)	Low to high	1748	Patients enrolled in ED, acute medical services, and cardiology departments; CCTA results readily available; SOC: stress testing at attending physician's discretion	1 year	No difference in costs‡	NA	NA
PROTECCT, Aziz et al* Heart 2022 (11)	Intermediate	250	Patients enrolled in ED; CCTA weekdays 8 am–5 pm; results readily available to CCTA arm; SOC: stress testing at attending physician's discretion	1 year	No difference in LOS‡	No difference in costs‡	Similar MACE in two arms

Note.—ACRIN-PA = American College of Radiology Imaging Network-Pennsylvania, ACS = acute coronary syndrome, BEACON = Better Evaluation of Acute Chest Pain with Computed Tomography Angiography, BM = biomarkers, CAD = coronary artery disease, CARMENTA = The Role of Initial Cardiovascular Magnetic Resonance Imaging and Computed Tomography Angiography in Non-ST-elevation Myocardial Infarction Patients, CATCH = Cardiac CT in the Treatment of Acute Chest pain, CCTA = coronary CT angiography, CT-COMPARE = The CT Coronary Angiography Compared with Exercise ECG, CT-STAT = Coronary Computed Tomographic Angiography for Systematic Triage of Acute Chest Pain Patients to Treatment, ECG = electrocardiography, ED = emergency department, ICA = invasive coronary angiography, LOS = length of stay, MACE = major adverse cardiovascular events, MI = myocardial infarction, MPI = myocardial perfusion imaging, NA = not applicable, NSTEMI = non-ST-elevation myocardial infarction, PCI = percutaneous coronary intervention, PERFECT = The Prospective First Evaluation in Chest Pain Trial, PPV = positive predictive value, PROSPECT = Prospective Randomized Outcome Trial Comparing Radionuclide Stress Myocardial Perfusion Imaging and ECG-gated Coronary CT Angiography, PROTECCT = The Prospective Randomized Trial of Emergency Cardiac Computerised Tomography, RAPID-CTCA = Rapid Assessment of Potential Ischemic Heart Disease-Computerised Tomography Coronary Angiography, ROMICAT II = Multicenter Study to Rule Out Myocardial Infarction by Cardiac Computed Tomography, SOC = standard of care.

\* Studies using high-sensitive troponin.

† = Main outcomes better for CCTA.

‡ = No difference in the main outcomes between CCTA and SOC.

§ = Main outcomes better for SOC.



**Table 2: Pretest Probability of Acute Coronary Syndrome**

Study	Risk Criteria
<b>Group 1 (very low, low, and intermediate risk)</b>	
Goldstein et al, JACC 2007 (21)	Goldman Riley criteria: CCTA arm, 98 (100%) very low; SOC arm, 97 (99.0%) very low and 1 (1.0%) low risk Mean TIMI risk score: CCTA arm, 1.24 (SD 0.8); SOC arm, 1.33 (SD 0.8)
Miller et al, Acad Emerg Med 2011 (23)	Clinical score based on initial history, physical examination, ECG, and BM Included only low- to intermediate-risk patients
CT-STAT, Goldstein et al, JACC 2011 (24)	Low risk Mean TIMI risk score: CCTA arm, 0.99 (SD, 0.84); SOC arm, 1.04 (SD, 0.87)
ACRIN-PA, Litt et al, NEJM 2012 (18)	Low-to-intermediate risk TIMI risk score: CCTA arm, 51% for 0, 36% for 1, 13% for $\geq 2$ ; SOC arm, 51% for 0, 36% for 1, 13% for $\geq 2$
ROMICAT-II, Hoffmann et al, NEJM 2012 (19)	Intermediate risk (ECG, normal; troponin, <99th percentile)
CT-COMPARE, Hamilton-Craig et al, Int J Cardiol 2014 (25)	Low-to-intermediate risk (initial ECG without evidence of acute ischemia; TIMI risk score <4; a negative first serum sensitive troponin-I [99th percentile])
PROSPECT, Levsky et al, Ann Int Med 2015 (27)	Intermediate risk TIMI risk score: CCTA arm, 1.3 (SD, 1.0); SOC arm, 1.2 (SD, 1.0)
BEACON, Dedic et al, JACC 2016 (28)	Low-to-high risk GRACE risk score: CCTA arm, 3% high, 12% intermediate, and 84% low probability; SOC arm, 1% high, 16% intermediate, and 83% low probability
Nabi et al, J Nucl Med 2016 (29)	Low-to-high risk Framingham risk score: CCTA arm, 4% high, 19% intermediate, and 76% low probability; SOC arm, 4% high, 18% intermediate, and 77% low probability
ACRIN-PA, Hollander et al, Ann Emerg Med 2016 (30)	Same population as ACRIN-PA, Litt et al (18)
PERFECT, Uretsky et al, J Nucl Cardiol 2017 (31)	Low risk (cardiac troponin, normal; ECG, nondiagnostic for ACS)
ACRIN-PA, Chang et al, Circulation 2017 (32)	Same population as ACRIN-PA, Litt et al (18)
Levsky et al, JACC 2018 (33)	Low risk Mean TIMI risk score: CCTA arm, 1; SOC arm, 1
PROSPECT, Goldman et al, J Nucl Cardiol 2020 (35)	Same population as PROSPECT, Levsky et al (27)
Pifeiro-Portela et al, Rev Esp Cardiol 2021 (36)	Low-to-intermediate risk (ECG, nondiagnostic; troponins, normal)
PROTECCT, Aziz et al, Heart 2022 (11)	Intermediate risk (high-sensitivity cardiac troponin concentration between 5 and 50 ng/L at initial blood draw)
<b>Group 2 (high risk)</b>	
Chang et al, Am Heart J 2008 (22)	Clinical score based on initial history, physical examination, and ECG: 21% high, 42% intermediate, and 37% low probability
CATCH, Linde et al, Int J Cardiol 2013 (17)	Clinical score based on initial history, physical examination, ECG, and BM: 10% high, 69% intermediate, and 21% low probability for both arms
CATCH, Linde et al, JACC 2015 (26)	Same population as CATCH, Linde et al (17)
CARMENTA, Smulders et al, JACC 2019 (34)	NSTEMI (ECG, normal or inconclusive; elevated high-sensitivity troponin levels) Mean GRACE score: CCTA arm, 114; SOC arm, 116

**(Table 2 continues)**

ering only group 2, the use of CCTA was associated with an increase in mean effective dose of 7.24 mSv (95% CI: 4.55, 9.94) when compared with SOC (Fig 8).

### Costs

The pooled data showed a reduction of 17% (95% CI: 5%, 28%) in costs when using CCTA compared with SOC (Fig 9). In group 1, considering the pooled data of nine RCTs with 4069 participants, the costs associated with CCTA were

21% lower (95% CI: 10%, 30%) in relation to SOC. For group 2, we identified only one RCT reporting costs in 1748 participants. In this study, the CCTA arm was associated with 8% higher (95% CI: 7%, 9%) costs compared with SOC.

### Rate of Hospitalization, Further Stress Testing, and Readmissions

There was no evidence of a difference in rate of hospitalization, further stress testing, and ED or hospital readmissions

**Table 2 (continued): Pretest Probability of Acute Coronary Syndrome**

Study	Risk Criteria
RAPID-CTCA, Gray et al, BMJ 2021 (10)	Low-to-high risk GRACE risk score: CCTA arm, 25% high, 31% intermediate, and 44% low probability; SOC arm: 22% high, 34% intermediate, and 44% low probability
RAPID-CTCA, Gray et al, Health Technol Assess 2022 (12)	Same population as Gray et al (10)

Note.—Group 1 had the criteria of containing less than 10% of high-risk participants and group 2 had the criteria of containing greater than or equal to 10% of high-risk participants. ACRIN-PA = American College of Radiology Imaging Network-Pennsylvania, BEACON = Better Evaluation of Acute Chest Pain with Computed Tomography Angiography, BM = biomarkers, CARMEN = The Role of Initial Cardiovascular Magnetic Resonance Imaging and Computed Tomography Angiography in Non-ST-elevation Myocardial Infarction Patients, CATCH = Cardiac CT in the Treatment of Acute Chest pain, CCTA = coronary CT angiography, CT-COMPARE = The CT Coronary Angiography Compared with Exercise ECG, CT-STAT = Coronary Computed Tomographic Angiography for Systematic Triage of Acute Chest Pain Patients to Treatment, ECG = electrocardiography, GRACE = The Global Registry of Acute Coronary Events, NSTEMI = non-ST-elevation myocardial infarction, PERFECT = The Prospective First Evaluation in Chest Pain Trial, PROSPECT = Prospective Randomized Outcome Trial Comparing Radionuclide Stress Myocardial Perfusion Imaging and ECG-gated Coronary CT Angiography, PROTECCT = The Prospective Randomized Trial of Emergency Cardiac Computerised Tomography, RAPID-CTCA = Rapid Assessment of Potential Ischemic Heart Disease-Computerised Tomography Coronary Angiography, ROMICAT II = Multicenter Study to Rule Out Myocardial Infarction by Cardiac Computed Tomography, SOC = standard of care, TIMI = Thrombolysis in Myocardial Infarction.

between CCTA and SOC approaches (Figs S2, S3, and S4, respectively).

### Changes in Medications

The analysis showed that overall, there were more instances of medication changes following CCTA compared with SOC (Fig S5). In group 1, consisting of five RCTs and a total of 2358 participants, the RR of medication change for CCTA versus SOC was 1.33 (95% CI: 1.06, 1.67). In group 2, with only one RCT including 1748 participants, the RR of medication change for CCTA versus SOC was 1.02 (95% CI: 0.95, 1.10).

### Incidental Findings

One study, a subanalysis of the Prospective Randomized Outcome Trial Comparing Radionuclide Stress Myocardial Perfusion Imaging and ECG-gated Coronary CT Angiography (PROSPECT) trial, reported more incidental findings in the CCTA arm compared with SOC arm (35). The authors reported 386 incidental findings in 187 participants who underwent CCTA. The most frequently occurring incidental findings at CCTA included pulmonary findings (118, 63%), noncoronary cardiac findings (69, 37%), gastrointestinal findings (49, 26%), hepatobiliary findings (42, 22%), and renal findings (17, 9%). No extracardiac incidental findings were noted at SPECT myocardial perfusion imaging studies. Also, there was a significantly higher frequency of incidental noncoronary inpatient medical workups in participants randomized to the CCTA arm compared with the SPECT myocardial perfusion imaging arm (20% vs 12%,  $P = .04$ ).

### Meta-Regression

Our meta-regression analyses revealed three significant correlations, as shown in Table S1. When physicians had the

discretion to determine the need for further stress testing, we observed a reduction in the rate of hospitalization and subsequent stress testing in the CCTA arm compared with the SOC arm (Figs S6 and S7, respectively). Also, we found that there were more medication changes in the CCTA arm compared with the SOC arm, particularly when SOC included stress echocardiography or nuclear medicine (Fig S8).

### Risk of Bias and Certainty of the Evidence

For the main desired outcomes, no study was judged as being at high risk of bias, as assessed by the RoB 2 tool, considering the following five domains: (a) randomization process, (b) deviations from the intended interventions, (c) missing outcome data, (d) measurement of the outcome, and (e) selection of the reported result (<https://nested-knowledge.com/nest/rob/912>). Upon conducting a visual inspection of the funnel plots (refer to Figs S9–S12), we noticed asymmetry for certain outcomes such as LOS, ICA, costs, and radiation exposure. Also, the Egger test was statistically significant for ICA ( $P = .04$ ), revascularization ( $P = .005$ ), and LOS ( $P = .04$ ). While this could suggest the possibility of publication bias, it is important to note that it may also be a result of true heterogeneity among the included studies (37). Also, the certainty of the evidence was rated as high by the GRADE system for all outcomes (Table S2).

### Discussion

This LSR and meta-analysis reassures health care decision makers that CCTA is a safe strategy to rule out ACS in adult patients presenting with ACP as pooled evidence shows similar incidence of MI (RR, 0.86; 95% CI: 0.66, 1.12) and mortality (RR, 0.96; 95% CI: 0.59, 1.58) between CCTA and SOC arms. Moreover, the use of CCTA is associated with reduced LOS (17%; 95% CI: 8%, 26%) and short-

**Table 3: Baseline Demographic Characteristics of Patients by Study**

Study	Arm	Mean Age (y)		Female Participants	Hypertension	Hyperlipidemia	Diabetes	Family History of CAD	Formerly Smoked or Currently Smoking	Mean BMI (kg/m <sup>2</sup> )
		Male	Female							
Goldstein et al JACC 2007 (21)	SOC, 98	51	42	37	37	12	43	20	29	
	CCTA, 99	48	57	38	33	8	39	15	29	
Chang et al Am Heart J 2008 (22)	SOC, 133	58	51	54	33	22	17	31	NA	
	CCTA, 133	57	52	61	39	21	16	23	NA	
Miller et al Acad Emerg Med 2011 (23)	SOC, 30	51	13	NA	NA	NA	NA	NA	NA	
CCTA, 30	51	17	17							
CT-STAT, Goldstein et al JACC 2011 (24)	SOC, 338	50	179	131	122	28	101	66	28.7	
	CCTA, 361	50	198	128	112	20	111	91	28.1	
ACRIN-PA, Litt et al NEJM 2012 (18)	SOC, 462	50	260	232	118	64	126	156	NA	
	CCTA, 908	49	465	463	249	130	268	291	NA	
ROMICAT-II, Hoffmann et al NEJM 2012 (19)	SOC, 499	54	229	272	224	87	136	243	29.1	
	CCTA, 501	54	240	269	230	86	135	249	29.4	
CATCH, Linde et al Int J Cardiol 2013 (17)	SOC, 291	55	123	106	101	29	76	195	28	
CATCH, Linde et al JACC 2015 (26)	CCTA, 285	56	124	135	117	35	69	172	28	
	SOC, 240	52	100	74	57	15	80	55	NA	
CT-COMPARE, Hamilton-Craig et al Int J Cardiol 2014 (25)	CCTA, 322	52	140	99	81	23	106	77	NA	
	SOC, 200	56	125	147	109	61	73	26	30.7	
PROSPECT, Levsky et al Ann Int Med 2015 (27)	CCTA, 200	57	126	141	97	66	75	33	30.5	
BEACON, Dedic et al JACC 2016 (28)	SOC, 250	53	113	112	87	33	98	100	NA	
	CCTA, 250	55	123	109	90	31	112	118	NA	
Nabi et al J Nucl Med 2016 (29)	SOC, 310	53	174	157	115	48	66	85	31.8	
	CCTA, 288	54	158	144	113	42	71	77	30.5	
PERFECT, Uretsky et al J Nucl Cardiol 2017 (31)	SOC, 205	60	108	142	109*	68	51	93	NA	
	CCTA, 206	59	111	140	88*	50	37	92	NA	
Levsky et al JACC 2018 (33)	SOC, 199	54	83	119	85	55	69	48	30.4	
	CCTA, 201	55	87	109	91	58	70	51	30.4	
CARMENTA, Smulders et al JACC 2019 (34)	SOC, 69	64	28	36	30*	8	29	31	27.2	
	CCTA, 70	64	19	33	19*	4	29	25	26.9	
Piñero-Portela et al Rev Esp Cardiol 2021 (36)	SOC, 103	64	37	72	78	30	4	35	NA	
	CCTA, 100	64	35	71	74	27	6	39	NA	

**(Table 3 continues)**

term costs (21%; 95% CI: 10%, 30%) in low- to intermediate-risk cohorts but not in high-risk patients which supports the recommendation of current chest pain guidelines (4,38). However, it is worth noting that this LSR did not evaluate the cost of downstream investigations for incidental findings due to the absence of comprehensive trial data.

The ROMICAT-II (19) and ACRIN-PA (18) studies were the major contributors to the observed reduction in LOS in participants presenting with ACP. These studies enrolled participants in the ED with scanners and CCTA reports readily available which may have contributed to reduced LOS. However, the studies were performed before the era of high-sensitive troponins, and studies incorporating this new tool showed shorter LOS in SOC arms and no difference compared with CCTA arms (11,28). Also, this reduction in LOS seems to be more important in the subgroup of participants with normal coronaries or non-obstructive CAD, since they can be securely discharged at a faster pace compared with those undergoing SOC. On the other hand, participants with obstructive CAD did not experience a different LOS compared with SOC arms given the necessity of additional testing to confirm ACS. Thus, it is expected that studies with individuals bearing higher pretest probability for ACS will diminish the effects of CCTA in decreasing LOS. This is supported by our findings which revealed no evidence of a difference in LOS between CCTA and SOC arms in studies containing greater than or equal to 10% of high-risk participants. Of note, one of the studies in this group (12) randomized participants during their original visit at the ED, hospital, or cardiology unit but allowed CCTA to be performed either during that visit or after discharge within 72 hours of randomization. This study revealed a 10% increase in the LOS for the CCTA arm (95% CI: 0%, 21%). These contrasting results underscore the importance of appropriate patient selection and the necessity to increase availability and timeliness of CCTA.

Our analysis confirms that using a CCTA-based strategy for triaging patients with ACS can reduce short-term costs. This is likely due to several factors including a decrease in LOS for participants with low-to-intermediate risk as well as fewer hospitalizations and less additional stress testing compared with the SOC group when the attending physicians have discretion in ordering further tests. It is noteworthy that the CCTA arm exhibited a slight rise in the number of revascularizations and medication adjustments, especially among participants in the low-to-intermediate risk group and when the SOC mandated stress echocardiography or nuclear medicine studies. A plausible explanation of this finding could be the capabilities of CCTA to provide enhanced anatomic visualization of the coronary tree, resulting in better selection of patients requiring revascularization or initiation of preventive medical therapy. Indeed, a subanalysis study of ACRIN-PA (32) demonstrated that in general, participants without stenosis undergoing CCTA versus SOC were less likely to be prescribed medications, whereas those with stenosis had a higher likelihood of starting medications. In the scenario of stable chest pain, the use

**Table 3 (continued): Baseline Demographic Characteristics of Patients by Study**

Study	Arm	Mean Age (y)		Female Participants		Hypertension	Hyperlipidemia	Diabetes	Family History of CAD		Formerly Smoked or Currently Smoking		Mean BMI (kg/m <sup>2</sup> )
		Male	Female	Participants	Participants				History of CAD	History of CAD	Formerly Smoked	Currently Smoking	
RAPID-CTCA, Gray et al	SOC, 871	61	550	321	404	336	165	270	531	530	NA	NA	
BMJ 2021 (10)	CCTA, 877	62	564	313	413	358	153	269	63	59	23	24	
PROTECCT, Aziz et al	SOC, 125	56	95	30	56	50	24	35	59	52	NA	NA	
Heart 2022 (11)	CCTA, 125	55	93	32	56	52	24	35	59	52	NA	NA	

Note.—Unless otherwise indicated, data are numbers of participants. The following trials had multiple investigations carried out using the same study sample: CATCH (Linde et al [17] and Linde et al [26]), ACRIN-PA (Litt et al [18], Hollander et al [30], and Chang et al [32]), PROSPECT (Levsky et al [27] and Goldman et al [35]), and RAPID-CTCA (Gray et al [10] and Gray et al [12]). ACRIN-PA = American College of Radiology Imaging Network-Pennsylvania, BEACON = Better Evaluation of Acute Chest Pain with Computed Tomography Angiography, BMI = body mass index, CAD = coronary artery disease, CARMEN = The Role of Initial Cardiovascular Magnetic Resonance Imaging and Computed Tomography Angiography in Non-ST-elevation Myocardial Infarction Patients, CATCH = Cardiac CT in the Treatment of Acute Chest Pain, CCTA = coronary CT angiography, CT-COMPARE = The CT Coronary Angiography Compared with Exercise ECG, CT-STAT = Coronary Computed Tomographic Angiography for Systematic Triage of Acute Chest Pain Patients to Treatment, NA = not applicable, PERFECT = The Prospective First Evaluation in Chest Pain Trial, PROSPECT = Prospective Randomized Outcome Trial Comparing Radionuclide Stress Myocardial Perfusion Imaging and ECG-gated Coronary CT Angiography, PROTECCT = The Prospective Randomized Trial of Emergency Cardiac Computerized Tomography, RAPID-CTCA = Rapid Assessment of Potential Ischemic Heart Disease-Computerized Tomography Coronary Angiography, ROMICAT II = Multicenter Study to Rule Out Myocardial Infarction by Cardiac Computed Tomography, SOC = standard of care.

\*P < .05; otherwise, no significant difference between arms.

**Table 4: Comparison of Coronary CT Angiography and Standard of Care for Evaluation of Acute Chest Pain**

Outcome	No. of Participants (Studies)	Certainty of the Evidence (GRADE)	Relative Effect	Absolute Effects	
				Risk with SOC Arm	Risk Difference with CCTA Arm
Length of stay (h)	7704 (13 RCTs)	++++ High	Mean: CCTA arm 14% lower than SOC arm (95% CI: 5%, 22% lower)	NA	NA
Cost (U.S. dollar)	5817 (10 RCTs)	++++ High	Mean: CCTA arm 17% lower than SOC arm (95% CI: 5%, 28% lower)	NA	NA
Referral for invasive coronary angiography ( <i>n</i> )	9379 (17 RCTs)	++++ High	RR: 1.08 (95% CI: 0.89, 1.30)	212 per 1000	17 more per 1000 (23 fewer to 64 more)
Revascularization ( <i>n</i> )	9180 (15 RCTs)	++++ High	RR: 1.37 (95% CI: 1.08, 1.74)	104 per 1000	38 more per 1000 (8 to 77 more)
Myocardial infarction ( <i>n</i> )	7930 (12 RCTs)	++++ High	RR: 0.86 (95% CI: 0.66, 1.12)	31 per 1000	4 fewer per 1000 (11 fewer to 4 more)
All-cause mortality ( <i>n</i> )	9317 (16 RCTs)	++++ High	RR: 0.96 (95% CI: 0.59, 1.58)	8 per 1000	0 fewer per 1000 (3 fewer to 4 more)
Cardiovascular mortality ( <i>n</i> )	8464 (13 RCTs)	++++ High	RR: 1.35 (95% CI: 0.59, 3.09)	2 per 1000	1 more per 1000 (1 fewer to 5 more)

Note.—The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). GRADE Working Group grades of evidence include the following: (a) high certainty, in which we are very confident that the true effect lies close to that of the estimate of the effect; (b) moderate certainty, in which we are moderately confident in the effect estimate (the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different); (c) low certainty, in which our confidence in the effect estimate is limited (the true effect may be substantially different from the estimate of the effect); and (d) very low certainty, in which we have very little confidence in the effect estimate (the true effect is likely to be substantially different from the estimate of effect). CCTA = coronary CT angiography, GRADE = grading of recommendations assessment, development, and evaluation, NA = not applicable, RCT = randomized controlled trial, RR = risk ratio, SOC = standard of care.


of CCTA has been associated with increased use of both preventive therapies and coronary revascularization, probably due to the better characterization of CAD (39). Also, these changes in medication were associated with reduced rates of subsequent death from coronary heart disease or nonfatal MI (40). CCTA may also overestimate the degree of stenosis, especially in patients with heavy coronary calcification (41), which in turn could result in unnecessary downstream procedures. The available information can neither confirm nor refute these hypotheses, nor does it provide insight on whether additional revascularizations were associated with better clinical outcomes.

The results of this LSR suggest that hard clinical outcomes such as MI and mortality are not affected by the choice of ACP evaluation strategy. Newer CT techniques such as CT stress perfusion or CT fractional flow reserve, which can be performed concurrently with CCTA, may improve the specificity and positive predictive value, allowing

for better identification of lesions with functional significance (42). This strategy could also further contribute to the reduction of ICA examinations and unnecessary revascularizations by identifying the hemodynamic significance of incidental coronary stenosis, further decreasing overall resource utilization and health care costs.

Our data about incidental findings with CCTA are limited to one study (35) which showed increased incidental findings contributing to increased in-hospital workup compared with SOC. Such increases could ultimately lead to longer LOSs (43). However, most incidental findings are non-life-threatening or unimportant and few cases require additional follow-up, being manageable during the regular outpatient workup (44).

One of the major concerns with CCTA is the radiation exposure it involves. In our study, we found that participants at high risk for ACS were exposed to increased radiation, possibly due to the higher prevalence of CAD.



**Figure 2:** Comparison of the length of stay between coronary CT angiography (CCTA) and standard of care (SOC) arms. Forest plot shows the ratio of means (ROM) for length of stay (in hours) for CCTA compared with SOC arms in participants with acute chest pain, stratified by group (group 1 = low-to-intermediate risk for acute coronary syndrome [ACS] and group 2 = high risk for ACS). The overall ratio of means was 0.86 (95% CI: 0.78, 0.95). The size of central markers reflects the weight of each study. While all studies are listed, some of them have not studied all outcomes, which explains the missing values.

This often leads to additional tests using nuclear medicine stress perfusion, which further exposes patients to radiation. Moreover, although we did not have enough data to run a meta-regression for this outcome, it is worth noting that the type of stress test used in SOC plays a crucial role in radiation exposure, as exercise bicycle and treadmill tests or stress echocardiography do not expose patients to radiation, while nuclear medicine tests do. Fortunately, emerging technologies are making substantial contributions to reducing the radiation dose at CCTA examinations. For instance, artificial intelligence iterative reconstruction has the potential to further reduce radiation exposure, while CT fractional flow reserve could increase its specificity, thereby avoiding the need for additional stress testing (42).


Our study had limitations. Although we pooled estimates for LOS and costs, it is important to note that there was a high level of heterogeneity in the metrics used for these measures across the studies. This variability limits the generalizability of the pooled estimates. Consequently, we urge caution in interpreting these results and recommend considering the specific context and metrics of each study when evaluating LOS and costs. Additional studies investigating the effects of coronary artery calcium score or CT fractional flow reserve for triaging patients with ACP were not included, as this

would require a different search query to identify all related studies; therefore, this should be investigated with a separate meta-analysis. However, these measures might affect multiple outcome parameters, including but not limited to the LOS, costs, rate of further testing, and rate of revascularization.

In conclusion, our results support the current guidelines’ recommendations for the use of CCTA as a safe, rapid, and less expensive in the short term strategy to exclude ACS in low- to intermediate-risk patients presenting with ACP.

**Author contributions:** Guarantors of integrity of entire study, M.F.B., F.U.K.; study concepts/study design or data acquisition or data analysis/interpretation, all authors; manuscript drafting or manuscript revision for important intellectual content, all authors; approval of final version of submitted manuscript, all authors; agrees to ensure any questions related to the work are appropriately resolved, all authors; literature research, M.F.B., A.C., H.L., D.B.D., S.A., F.U.K.; statistical analysis, Y.X., S.A.; and manuscript editing, all authors

**Disclosures of conflicts of interest:** M.F.B. No relevant relationships. A.C. Royalties from Elsevier. Y.X. Associate editor and statistician for *Radiology: Cardiothoracic Imaging*. H.L. Support from Siemens Healthineers and Philips Healthcare to institution; travel support from Siemens Healthineers to institution; deputy editor of *Radiology: Cardiothoracic Imaging*. D.B.D. Institutional research contracts from Abbott, Siemens Healthineers, Roche, Quidel, and Ortho Clinical Diagnostics; participation on NIH PETAL Network data and safety monitoring board; member of the Academy of Academic Chairs of Emergency Medicine Executive Committee and Emergencies in Medicine Board of Directors. S.A. Royalties from Elsevier; editor of *Radiology: Cardiothoracic Imaging*. F.U.K. Grants from the Radiological




**Figure 3:** Comparison of the rate of invasive coronary angiography between coronary CT angiography (CCTA) and standard of care (SOC) arms. Forest plot shows the risk ratio (RR) of intensive coronary angiography for CCTA arms compared with SOC arms in participants with acute chest pain, stratified by group (group 1 = low-to-intermediate risk for acute coronary syndrome [ACS] and group 2 = high risk for ACS). The overall RR was 1.08 (95% CI: 0.89, 1.30). The size of central markers reflects the weight of each study. While all studies are listed, some of them have not studied all outcomes, which explains the missing values.

Society of North America and Edwards Lifesciences; consulting fees from Bayer; honoraria for lecture from the International Society for Cell and Gene Therapy; travel support from UT Southwestern Medical Center; associate editor of *Radiology: Cardiothoracic Imaging*.

## References


- Rui P, Kang K. National Hospital Ambulatory Medical Care Survey: 2017 emergency department summary tables. National Center for Health Statistics. [https://www.cdc.gov/nchs/data/nhamcs/web\\_tables/2017\\_ed\\_web\\_tables-508.pdf](https://www.cdc.gov/nchs/data/nhamcs/web_tables/2017_ed_web_tables-508.pdf). Accessed November 3, 2022.
- Mahler SA, Lenoir KM, Wells BJ, et al. Safely Identifying Emergency Department Patients With Acute Chest Pain for Early Discharge. *Circulation* 2018;138(22):2456–2468.
- Ferguson B, Gerald S, Petrey J, Huecker M. Malpractice in Emergency Medicine-A Review of Risk and Mitigation Practices for the Emergency Medicine Provider. *J Emerg Med* 2018;55(5):659–665.
- Writing Committee Members; Gulati M, Levy PD, et al. 2021 AHA/ACC/AASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol* 2021;78(22):e187–e285.
- Maroules CD, Rybicki FJ, Ghoshhajra BB, et al. 2022 use of coronary computed tomographic angiography for patients presenting with acute chest pain to the emergency department: An expert consensus document of the Society of cardiovascular computed tomography (SCCT): Endorsed by the American College of Radiology (ACR) and North American Society for cardiovascular Imaging (NASCI). *J Cardiovasc Comput Tomogr* 2023;17(2):146–163.
- D'Ascenzo F, Cerrato E, Biondi-Zoccai G, et al. Coronary computed tomographic angiography for detection of coronary artery disease in patients presenting to the emergency department with chest pain: a meta-analysis of randomized clinical trials. *Eur Heart J Cardiovasc Imaging* 2013;14(8):782–789.
- Hulten E, Pickett C, Bittencourt MS, et al. Outcomes after coronary computed tomography angiography in the emergency department: a systematic review and meta-analysis of randomized, controlled trials. *J Am Coll Cardiol* 2013;61(8):880–892.
- El-Hayek G, Benjo A, Uretsky S, et al. Meta-analysis of coronary computed tomography angiography versus standard of care strategy for the evaluation of low risk chest pain: are randomized controlled trials and cohort studies showing the same evidence? *Int J Cardiol* 2014;177(1):238–245.
- Gongora CA, Bavishi C, Uretsky S, Argulian E. Acute chest pain evaluation using coronary computed tomography angiography compared with standard of care: a meta-analysis of randomised clinical trials. *Heart* 2018;104(3):215–221.
- Gray AJ, Roobottom C, Smith JE, et al. Early computed tomography coronary angiography in patients with suspected acute coronary syndrome: randomised controlled trial. *BMJ* 2021;374:n2106. [Published correction appears in *BMJ* 2022;376:o438.]
- Aziz W, Morgan H, Demir OM, et al. Prospective Randomised Trial of Emergency Cardiac Computerised Tomography (PROTECCT). *Heart* 2022;108(24):1972–1978.
- Gray AJ, Roobottom C, Smith JE, et al. Early computed tomography coronary angiography in adults presenting with suspected acute coronary syndrome: the RAPID-CTCA RCT. *Health Technol Assess* 2022;26(37):1–114.
- Elliott JH, Synnot A, Turner T, et al. Living systematic review: 1. Introduction—the why, what, when, and how. *J Clin Epidemiol* 2017;91:23–30.
- Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Syst Rev* 2021;10(1):89.
- Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019;366:l4898.



**Figure 4:** Comparison of the rate of revascularization between coronary CT angiography (CCTA) and standard of care (SOC) arms. Forest plot shows the risk ratio (RR) of revascularization for CCTA arms compared with SOC arms in participants with acute chest pain, stratified by group (group 1 = low-to-intermediate risk for acute coronary syndrome [ACS] and group 2 = high risk for ACS). The overall RR was 1.37 (95% CI: 1.08, 1.74). The size of central markers reflects the weight of each study. While all studies are listed, some of them have not studied all outcomes, which explains the missing values.


- Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336(7650):924–926.
- Linde JJ, Kofoed KF, Sørgaard M, et al. Cardiac computed tomography guided treatment strategy in patients with recent acute-onset chest pain: results from the randomised, controlled trial: CArdiac cT in the treatment of acute CHest pain (CATCH). *Int J Cardiol* 2013;168(6):5257–5262.
- Litt HI, Gatsonis C, Snyder B, et al. CT angiography for safe discharge of patients with possible acute coronary syndromes. *N Engl J Med* 2012;366(15):1393–1403.
- Hoffmann U, Truong QA, Schoenfeld DA, et al. Coronary CT angiography versus standard evaluation in acute chest pain. *N Engl J Med* 2012;367(4):299–308.
- Balduzzi S, Rucker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. *Evid Based Ment Health* 2019;22(4):153–160.
- Goldstein JA, Gallagher MJ, O'Neill WW, Ross MA, O'Neil BJ, Raff GL. A randomized controlled trial of multi-slice coronary computed tomography for evaluation of acute chest pain. *J Am Coll Cardiol* 2007;49(8):863–871.
- Chang SA, Choi SI, Choi EK, et al. Usefulness of 64-slice multidetector computed tomography as an initial diagnostic approach in patients with acute chest pain. *Am Heart J* 2008;156(2):375–383.
- Miller AH, Pepe PE, Peshock R, et al. Is coronary computed tomography angiography a resource sparing strategy in the risk stratification and evaluation of acute chest pain? Results of a randomized controlled trial. *Acad Emerg Med* 2011;18(5):458–467.
- Goldstein JA, Chinnaiyan KM, Abidov A, et al. The CT-STAT (Coronary Computed Tomographic Angiography for Systematic Triage of Acute Chest Pain Patients to Treatment) trial. *J Am Coll Cardiol* 2011;58(14):1414–1422.
- Hamilton-Craig C, Fifoot A, Hansen M, et al. Diagnostic performance and cost of CT angiography versus stress ECG—a randomized prospective study of suspected acute coronary syndrome chest pain in the emergency department (CT-COMPARE). *Int J Cardiol* 2014;177(3):867–873.
- Linde JJ, Hove JD, Sørgaard M, et al. Long-Term Clinical Impact of Coronary CT Angiography in Patients With Recent Acute-Onset Chest Pain: The Randomized Controlled CATCH Trial. *JACC Cardiovasc Imaging* 2015;8(12):1404–1413.
- Levsky JM, Spevack DM, Travin MI, et al. Coronary Computed Tomography Angiography Versus Radionuclide Myocardial Perfusion Imaging in Patients With Chest Pain Admitted to Telemetry: A Randomized Trial. *Ann Intern Med* 2015;163(3):174–183.
- Dedic A, Lubbers MM, Schaap J, et al. Coronary CT Angiography for Suspected ACS in the Era of High-Sensitivity Troponins: Randomized Multicenter Study. *J Am Coll Cardiol* 2016;67(1):16–26.
- Nabi F, Kassi M, Muhyieddeen K, et al. Optimizing Evaluation of Patients with Low-to-Intermediate-Risk Acute Chest Pain: A Randomized Study Comparing Stress Myocardial Perfusion Tomography Incorporating Stress-Only Imaging Versus Cardiac CT. *J Nucl Med* 2016;57(3):378–384.
- Hollander JE, Gatsonis C, Greco EM, et al. Coronary Computed Tomography Angiography Versus Traditional Care: Comparison of One-Year Outcomes and Resource Use. *Ann Emerg Med* 2016;67(4):460–468.e1.
- Uretsky S, Argulian E, Supariwala A, et al. Comparative effectiveness of coronary CT angiography vs stress cardiac imaging in patients following hospital admission for chest pain work-up: The Prospective First Evaluation in Chest Pain (PERFECT) Trial. *J Nucl Cardiol* 2017;24(4):1267–1278.






**Figure 5:** Comparison of the rate of myocardial infarction between coronary CT angiography (CCTA) and standard of care (SOC) arms. Forest plot shows the risk ratio (RR) of myocardial infarction for CCTA arms compared with SOC arms in participants with acute chest pain, stratified by group (group 1 = low-to-intermediate risk for acute coronary syndrome [ACS] and group 2 = high risk for ACS). The overall RR was 0.86 (95% CI: 0.66, 1.12). The size of central markers reflects the weight of each study. While all studies are listed, some of them have not studied all outcomes, which explains the missing values.


32. Chang AM, Litt HI, Snyder BS, et al. Impact of Coronary Computed Tomography Angiography Findings on Initiation of Cardioprotective Medications. *Circulation* 2017;136(22):2195–2197.
33. Levsky JM, Haramati LB, Spevack DM, et al. Coronary Computed Tomography Angiography Versus Stress Echocardiography in Acute Chest Pain: A Randomized Controlled Trial. *JACC Cardiovasc Imaging* 2018;11(9):1288–1297.
34. Smulders MW, Kietselaer BLJH, Wildberger JE, et al. Initial Imaging-Guided Strategy Versus Routine Care in Patients With Non-ST-Segment Elevation Myocardial Infarction. *J Am Coll Cardiol* 2019;74(20):2466–2477.
35. Goldman LH, Lerer R, Shabrang C, Travin MI, Levsky JM. Clinical significance of incidental findings on coronary CT angiography: Insights from a randomized controlled trial. *J Nucl Cardiol* 2020;27(6):2306–2315.
36. Piñeiro-Portela M, Peteiro-Vázquez J, Bouzas-Mosquera A, et al. Comparison of two strategies in a chest pain unit: stress echocardiography and multidetector computed tomography. *Rev Esp Cardiol (Engl Ed)* 2021;74(1):59–64.
37. Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ* 2011;343:d4002.
38. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J* 2021;42(14):1289–1367.
39. SCOT-HEART investigators. CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an open-label, parallel-group, multicentre trial. *Lancet* 2015;385(9985):2383–2391. [Published correction appears in *Lancet* 2015;385(9985):2354.]
40. SCOT-HEART Investigators; Newby DE, Adamson PD, et al. Coronary CT Angiography and 5-Year Risk of Myocardial Infarction. *N Engl J Med* 2018;379(10):924–933.
41. Foy AJ, Dhruva SS, Peterson B, Mandrolia JM, Morgan DJ, Redberg RF. Coronary Computed Tomography Angiography vs Functional Stress Testing for Patients With Suspected Coronary Artery Disease: A Systematic Review and Meta-analysis. *JAMA Intern Med* 2017;177(11):1623–1631.
42. Canan A, Barbosa MF, Nomura CH, Abbara S, Kay FU. Cardiac CT Perfusion Imaging. *Curr Radiol Rep* 2022;11(1):12–23.
43. Gundareddy VP, Maruthur NM, Chibungu A, Bollampally P, Landis R, Eid SM. Association Between Radiologic Incidental Findings and Resource Utilization in Patients Admitted With Chest Pain in an Urban Medical Center. *J Hosp Med* 2017;12(5):323–328.
44. Lee CI, Tsai EB, Sigal BM, Plevritis SK, Garber AM, Rubin GD. Incidental extracardiac findings at coronary CT: clinical and economic impact. *AJR Am J Roentgenol* 2010;194(6):1531–1538.




**Figure 6:** Comparison of all-cause mortality between coronary CT angiography (CCTA) and standard of care (SOC) arms. Forest plot shows the risk ratio (RR) of all-cause mortality for CCTA arms compared with SOC arms in participants with acute chest pain, stratified by group (group 1 = low-to-intermediate risk for acute coronary syndrome [ACS] and group 2 = high risk for ACS). The overall RR was 0.96 (95% CI: 0.59, 1.58). The size of central markers reflects the weight of each study. While all studies are listed, some of them have not studied all outcomes, which explains the missing values.



**Figure 7:** Comparison of cardiovascular mortality between coronary CT angiography (CCTA) and standard of care (SOC) arms. Forest plot shows the risk ratio (RR) of cardiovascular mortality for CCTA arms compared with SOC arms in participants with acute chest pain, stratified by group (group 1 = low-to-intermediate risk for acute coronary syndrome [ACS] and group 2 = high risk for ACS). The overall RR was 1.35 (95% CI: 0.59, 3.09). The size of central markers reflects the weight of each study. While all studies are listed, some of them have not studied all outcomes, which explains the missing values.



**Figure 8:** Comparison of radiation dose between coronary CT angiography (CCTA) and standard of care (SOC) arms. Forest plot shows the mean difference (MD) of radiation dose in millisieverts for CCTA arms compared with SOC arms in participants with acute chest pain, stratified by group (group 1 = low-to-intermediate risk for acute coronary syndrome [ACS] and group 2 = high risk for ACS). The overall MD was 3.56 (95% CI: -0.19, 7.31). The size of central markers reflects the weight of each study. While all studies are listed, some of them have not studied all outcomes, which explains the missing values.



**Figure 9:** Comparison of costs between coronary CT angiography (CCTA) and standard of care (SOC) arms. Forest plot shows the ratio of means (ROM) for costs (U.S. dollars) for CCTA arms compared with SOC arms in participants with acute chest pain, stratified by group (group 1 = low-to-intermediate risk for acute coronary syndrome [ACS] and group 2 = high risk for ACS). The overall ROM was 0.83 (95% CI: 0.72, 0.95). The size of central markers reflects the weight of each study. While all studies are listed, some of them have not studied all outcomes, which explains the missing values.